Company intelligence / Profile preview
Replicor Inc.
Montreal, Quebec, Canadareplicor.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Completed enrollment in Phase II trial (REP 301) examining safety and efficacy of REP 2139-Ca combined with Pegasys for HBV/HDV co-infection. Previous trials have shown antiviral efficacy.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Nucleic Acid Polymers (NAPs)Oligonucleotides
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Replicor Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Replicor Inc..